Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Monsenso A/S issues warrants to management and employees

Monsenso

10.4.2024 23:04:06 CEST | Monsenso | Company Announcement

Company announcement no. 07-2024

Copenhagen, 2024.04.10

This message includes inside information

The Board of Directors of Monsenso A/S hereby announces the decision to issue warrants for employees and management, who are in a non-terminated position and who were employed on 1 January 2024.

The vesting period for the warrants is 36 months from 1 May 2024 to 30 April 2027, but only if the recipient is still employed by the company. Unexercised warrants expire on 31 August 2031. DKK 2,660,000 warrants have been granted, giving the right to subscribe for a nominal DKK 266,000 shares in the company.

The Board of Directors has set the exercise price at DKK 0.30 per warrant, which corresponds to the market rate calculated as the latest 30-day weighted average and follows § 5.3 of the company's articles of association.

The warrant holder shall not pay any compensation for the granting of the warrants. The vested warrants can be exercised twice a year after publication of the company's annual and half-yearly report in an exercise window of pt. 2 weeks.

Monsenso's share capital amounts to a nominal value of DKK 6,646,631.70 divided into 66,466,317 shares of DKK 0.10.

Any inquiries regarding this notice should be directed to:

Monsenso

CEO
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com 

Chairman of the board
Peter Mørch Eriksen
E-mail: Petermorcheriksen@outlook.com

Certified Adviser

Norden CEF A/S
John Norden

E-mail: jn@nordencef.dk

About Monsenso

Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com

Attachments

  • Download announcement as PDF.pdf
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team